← Back to Screener
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP)
Price$26.15
Favorite Metrics
Price vs S&P 500 (26W)6.41%
Price vs S&P 500 (4W)40.91%
Market Capitalization$461.29M
P/E Ratio (Annual)14.55x
All Metrics
P/CF (Annual)160.67x
Book Value / Share (Quarterly)$8.77
P/TBV (Annual)5.56x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)105.26%
Cash Flow / Share (Quarterly)$0.24
Payout Ratio (TTM)17.26%
Price vs S&P 500 (YTD)48.28%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)60.81%
EPS (TTM)$1.76
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$1.76
Revenue Growth (5Y)12.15%
EPS (Annual)$1.76
Dividend / Share (Annual)$0.46
ROI (Annual)14.89%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-217.61%
Cash / Share (Quarterly)$7.02
P/E Basic Excl Extra (TTM)14.55x
Revenue Growth QoQ (YoY)57.87%
EPS Growth (5Y)8.80%
P/E Normalized (Annual)14.55x
ROA (Last FY)11.63%
Revenue Growth TTM (YoY)83.06%
EBITD / Share (TTM)$2.32
ROE (5Y Avg)-7.01%
Operating Margin (TTM)62.53%
Cash Flow / Share (Annual)$0.24
P/B Ratio4.44x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$2
EV / Revenue (TTM)9.35x
Net Interest Coverage (TTM)6.48x
ROA (TTM)13.05%
EV / EBITDA (TTM)11.69x
EPS Incl Extra (Annual)$1.76
Current Ratio (Annual)3.37x
Quick Ratio (Quarterly)3.34x
3-Month Avg Trading Volume0.31M
52-Week Price Return97.88%
EV / Free Cash Flow (Annual)169.75x
P/E Incl Extra (TTM)14.55x
Revenue / Employee (TTM)$4
Tangible BV / Share (Quarterly)$4.99
P/S Ratio (Annual)8.85x
Asset Turnover (Annual)0.19x
52-Week High$40.25
Operating Margin (5Y Avg)-226.62%
EPS Excl Extra (Annual)$1.76
Tangible BV CAGR (5Y)79.85%
26-Week Price Return10.40%
Quick Ratio (Annual)3.34x
13-Week Price Return49.79%
Total Debt / Equity (Annual)1.05x
Current Ratio (Quarterly)3.37x
Enterprise Value$487.36
Revenue / Share Growth (5Y)2.56%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)2.59%
Revenue / Employee (Annual)$4
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)61.01%
Cash / Share (Annual)$7.02
3-Month Return Std Dev54.87%
Gross Margin (5Y Avg)75.37%
Net Income / Employee (TTM)$2
EBITDA CAGR (5Y)26.26%
EBITDA Interim CAGR (5Y)-15.39%
ROE (Last FY)30.50%
Net Interest Coverage (Annual)3.09x
EPS Basic Excl Extra (Annual)$1.76
P/FCF (TTM)53.22x
Receivables Turnover (TTM)15.49x
EV / Free Cash Flow (TTM)169.75x
Total Debt / Equity (Quarterly)1.05x
EPS Incl Extra (TTM)$1.76
Receivables Turnover (Annual)15.49x
ROI (TTM)15.21%
P/S Ratio (TTM)8.85x
Pretax Margin (5Y Avg)-221.56%
Revenue / Share (Annual)$2.90
Tangible BV / Share (Annual)$4.99
Forward P/E30.63x
Free OCF CAGR (5Y)-22.21%
Price vs S&P 500 (52W)68.05%
P/E Ratio (TTM)14.55x
Year-to-Date Return50.92%
5-Day Price Return9.17%
EPS Normalized (Annual)$1.76
ROA (5Y Avg)-2.95%
Net Profit Margin (Annual)60.81%
Month-to-Date Return27.92%
Cash Flow / Share (TTM)$-2.74
EBITD / Share (Annual)$2.26
Operating Margin (Annual)62.53%
LT Debt / Equity (Annual)0.93x
P/CF (TTM)160.67x
ROI (5Y Avg)-2.77%
P/E Excl Extra (TTM)14.55x
LT Debt / Equity (Quarterly)0.93x
EPS Basic Excl Extra (TTM)$1.76
P/TBV (Quarterly)5.56x
Payout Ratio (Annual)17.26%
P/B Ratio (Annual)3.17x
Dividend / Share (TTM)$0.46
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)61.01%
Book Value / Share (Annual)$8.77
Price vs S&P 500 (13W)49.11%
Net Margin Growth (5Y)6.09%
Dividend Yield (TTM)1.19%
Beta0.83x
P/FCF (Annual)160.67x
Revenue / Share (TTM)$2.88
ROE (TTM)32.61%
52-Week Low$20.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XOMAPXOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock | 8.85x | 83.06% | 100.00% | 8.80% | $26.15 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
XOMA Royalty Corp acquires the future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical and biotechnology companies. This model provides non-dilutive, non-recourse funding to biotech firms, enabling them to advance drug development or support other corporate needs. The company operates internationally across Switzerland, the United States, Asia Pacific, Europe, and other markets.